AVITA Medical sells RECELL, a skin cell device for wound care, plus PermeaDerm and Cohealyx wound matrices to burn and trauma centers. RCEL reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Prices, price targets and earnings estimates for RCEL are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in RCEL in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RCEL is in one of them and how their past RCEL trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About AVITA Medical
AVITA Medical is an acute wound care company based in Valencia, California. Its main product is RECELL, a device that lets clinicians prepare a suspension of a patient's own skin cells at the point of care, which can cover large wounds using a small donor skin sample. The company also sells PermeaDerm, a biosynthetic wound matrix, and Cohealyx, a dermal matrix made from collagen. Its customers are mainly burn, trauma and surgical centers, chiefly in the United States.
